AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32409982
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg CBD
Trial: 32409982
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg CBD
Trial: 32409982
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg CBD
Trial: 34130026
Drug: Non MedDiet
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non MedDiet plus nuts (50 g/day)
Trial: 33906126
Drug: Aerosolized hyaluronan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized hyaluronan (HA) - 3 ml inhalation solution containing 0.03% HA, self-administered twice daily
Trial: 33271178
Drug: 4 mg/mL
RxNorm normalized name: valine 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/mL dexamethasone
Trial: 33271178
Drug: 25 mg/mL
RxNorm normalized name: hemin 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/mL diclofenac sodium
Trial: 35286282
Drug: CEAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEAA supplementation (oral, twice daily for 2 weeks)
Trial: 35383071
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac 0.5 mg/kg + IV morphine placebo
Trial: 35383071
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine 0.1 mg/kg + IV ketorolac placebo
Trial: 32170789
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg lycopene
Trial: 32170789
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg lycopene
Trial: 32170789
Drug: 80 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/kg lycopene
Trial: 32170789
Drug: 0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/kg lycopene (control group)
Trial: 35061634
Drug: Ultrasound-guided CPB
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided CPB with ICPB (CC)
Trial: 32474612
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for zone 1 fractures
Trial: 32474612
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for zone 1 fractures
Trial: 32474612
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for Jones' (zone 2) fractures
Trial: 32474612
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for Jones' (zone 2) fractures
Trial: 33464986
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment model for high school students with ASD
Trial: 34483022
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg QS-21-containing C difficile vaccine
Trial: 34483022
Drug: 100 or
RxNorm normalized name: Stalevo 100 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 µg unadjuvanted C difficile vaccine formulation
Trial: 35169011
Drug: Migraine preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine preventive medication without switching of the overused medication
Trial: 35169011
Drug: Migraine preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine preventive medication with switching from the overused medication
Trial: 33414442
Drug: BNC210 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC210 (300 mg)
Trial: 33414442
Drug: BNC210 (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC210 (2000 mg)
Trial: 33414442
Drug: BNC210 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC210 (200 mg)
Trial: 33414442
Drug: BNC210 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC210 (low dose)
Trial: 32129101
Drug: GIK infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIK infusion with supportive care
Trial: 33616643
Drug: Avexitide 30
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avexitide 30 mg twice daily
Trial: 33616643
Drug: Avexitide 60
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avexitide 60 mg once daily
Trial: 32421841
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intramuscular naloxone hydrochloride (PFS)
Trial: 35340943
Drug: Macintosh laryngoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macintosh laryngoscope (Group L, N = 60)
Trial: 38814736
Drug: Biologics
RxNorm normalized name: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics
Trial: 33104176
Drug: Plasmalike isotonic
RxNorm normalized name: Plasmalyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalike isotonic fluid therapy (140 mmol/L sodium and 5 mmol/L potassium in 5% dextrose)
Trial: 33104176
Drug: Moderately hypotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypotonic fluid therapy (80 mmol/L sodium and 20 mmol/L potassium in 5% dextrose)
Trial: 33104176
Drug: Plasmalike isotonic
RxNorm normalized name: Plasmalyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalike isotonic fluid therapy
Trial: 33104176
Drug: Moderately hypotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypotonic fluid therapy
Trial: 38467912
Drug: Upadacitinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib (15 mg once daily)
Trial: 33053283
Drug: Abatacept (intravenous)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept (intravenous)
Trial: 38077624
Drug: Quadrivalent inactivated
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent inactivated influenza vaccine (QIV)
Trial: 34369683
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic treatment with conventional medication)
Trial: 35756420
Drug: Oxycodone (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (0.02 mg/kg)
Trial: 35756420
Drug: Sufentanil (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.02 µg/kg)
Trial: 33962962
Drug: Intra-articular sprifermin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sprifermin 100 μg every 6 months (q6mo)
Trial: 33962962
Drug: Intra-articular sprifermin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sprifermin 100 μg q6mo
Trial: 33349862
Drug: Romidepsin (RMD)
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin (RMD) 0.5 mg/m2, 2 mg/m2, 5 mg/m2 (single dose)
Trial: 33349862
Drug: Romidepsin (RMD)
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin (RMD) 5 mg/m2 (multi-dose)
Trial: 34749132
Drug: Very-low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-calorie diet (VLCD) with 77 g/day protein for 8 weeks
Trial: 34749132
Drug: Very-low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-calorie diet (VLCD) with 52 g/day protein for 8 weeks
Trial: 35916669
Drug: Multi-strain probiotic
RxNorm normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-strain probiotic intervention (L. paracasei CNCM I‐1518, L. paracasei CNCM I‐3689, L. rhamnosus CNCM I‐3690, and four yogurt strains)
Trial: 32765053
Drug: Inhaled methoxyflurane
RxNorm normalized name: methoxyflurane Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methoxyflurane
Trial: 34911168
Drug: Monthly feedback
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly feedback reports
Trial: 34911168
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alerts and feedback reports
Trial: 34204017
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with myofunctional and speech therapy
Trial: 34441773
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading protocol using VulkanLoc® abutments after implant emplacement
Trial: 35298997
Drug: Daily life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily life regulation strategies
Trial: 33368969
Drug: Endoxifen (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoxifen (8 mg daily)
Trial: 32965505
Drug: Prognostic index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic index model for treatment outcome
Trial: 32965505
Drug: Prognostic index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic index model for post-treatment participation
Trial: 32840767
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of 2.0 g TXA in 10 mL 0.9% NaCl after suturing the joint capsule
Trial: 32840767
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 2 g TXA in 200 mL 0.9% NaCl 30 min before the operation
Trial: 34705157
Drug: Face-to-face instruction
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face instruction and personalized bowel preparation regimens
Trial: 34705157
Drug: Routine bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine bowel preparation regimen and education
Trial: 33879260
Drug: Telemedicine-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine-based medication treatment for opioid use disorder (MOUD)
Trial: 35947945
Drug: Linear low-intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear low-intensity extracorporeal shockwave therapy (LI-LiESWT) using the PiezoWave2 device with a linear shockwave applicator, administered over 4 treatments in a 4-week period.
Trial: 34642416
Drug: Green Therapy
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Therapy room
Trial: 32986459
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg methamphetamine
Trial: 32986459
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methamphetamine
Trial: 32986459
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methamphetamine
Trial: 32000474
Drug: Midazolam (medication)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (medication)
Trial: 32000474
Drug: Medication (Midazolam)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Midazolam)
Trial: 34800178
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks plus axitinib 5 mg twice daily
Trial: 36344929
Drug: Polyclonal rabbit
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyclonal rabbit antithymocyte globulin (Grafalon®) 6 mg/kg/day
Trial: 35160211
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy group (CTG)
Trial: 34257012
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of low-dose sevoflurane (end-expiratory concentration, 0.4%) through a face mask
Trial: 34257012
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine (2 mg/kg)
Trial: 34257012
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of low-dose sevoflurane
Trial: 32163578
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (systolic BP target <120 mmHg)
Trial: 32163578
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment (systolic BP target <140 mmHg)
Trial: 32846626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LAB and yeast cells
Trial: 32482150
Drug: Short-acting beta2
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta2 agonists (SABAs)
Trial: 32482150
Drug: Anti-inflammatory reliever
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory reliever therapy (combination of low dose ICS/fast action bronchodilator)
Trial: 32868662
Drug: Conventional angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional angiotensin-converting enzyme inhibitors (ACEI)
Trial: 36451452
Drug: Esketamine combined
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine combined with sufentanil (Group L)
Trial: 36451452
Drug: Esketamine combined
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine combined with sufentanil (Group H, Group M, Group L)
Trial: 33951140
Drug: Manually adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually adjusted goal-directed therapy
Trial: 32541380
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus 5-hydroxytryptophan (100 mg twice daily)
Trial: 33201771
Drug: Eravacycline 1
RxNorm normalized name: eravacycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eravacycline 1 mg/kg intravenously every 12 hours
Trial: 33201771
Drug: Carbapenem comparators
RxNorm normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenem comparators (ertapenem 1 g intravenously every 24 hours or meropenem 1 g intravenously every eight hours)
Trial: 37979717
Drug: Prophylactic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic heparin
Trial: 34598883
Drug: Low-Dose-Rate (LDR)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose-Rate (LDR) brachytherapy
Trial: 34598883
Drug: High-Dose-Rate (HDR)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose-Rate (HDR) brachytherapy
Trial: 34244280
Drug: Postoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotic prophylaxis
Trial: 32466056
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment (80 mg via nasogastric tube)
Trial: 32891136
Drug: Dexmedetomidine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.2 μg·kg‐1 combined with remifentanil
Trial: 32891136
Drug: Dexmedetomidine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.3 μg·kg‐1 combined with remifentanil
Trial: 32891136
Drug: Dexmedetomidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4 μg·kg‐1 combined with remifentanil
Trial: 37053429
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy
Trial: 33278614
Drug: Modular hemiarthroplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular hemiarthroplasty implant
Trial: 33278614
Drug: Traditional monoblock
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional monoblock implant
Trial: 33009228
Drug: PRC‐063 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRC‐063 (100 mg/d)
Trial: 33009228
Drug: Immediate‐release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate‐release methylphenidate (20 mg, 3 times daily)
Trial: 38048133
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (CCB)
Trial: 35331230
Drug: Yoga with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga with high dose vitamin D (4000 IU)
Trial: 35331230
Drug: Yoga with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga with low dose vitamin D (2000 IU)
Trial: 35331230
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D (4000 IU)
Trial: 33222470
Drug: Sufentanil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.4 µg/kg
Trial: 33222470
Drug: Fentanyl 4
RxNorm normalized name: fentanyl 400 MCG Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 4 µg/kg
Trial: 33021585
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C (1 g) and E (800 UI) supplementation 40 minutes before exercise
Trial: 34100742
Drug: Language intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Language intervention protocol combined with auditory verbal therapy (AVT)
Trial: 34100742
Drug: Auditory verbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory verbal therapy (AVT)
Trial: 38154770
Drug: Clomiphene +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene + Metformin
Trial: 35779532
Drug: Intensive home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive home treatment
Trial: 33857800
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose group (n = 10) performed 4320 steps
Trial: 33857800
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group (n = 10) performed 144 steps
Trial: 32792771
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of triamcinolone acetonide (10 mg/mL)
Trial: 32792771
Drug: Intralesional autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional autologous platelet-rich plasma (PRP) injection
Trial: 36658607
Drug: Spa therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa therapy alone
Trial: 32791665
Drug: Sirolimus 2
RxNorm normalized name: sirolimus 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 2 mg orally once daily for 16 weeks
Trial: 35891255
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (DD) of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine
Trial: 35891255
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose (ND) of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine
Trial: 35891255
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (DD)
Trial: 32289292
Drug: 0 medications
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0 medications
Trial: 32289292
Drug: 1 medication
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 medication
Trial: 32289292
Drug: 2 medications
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 medications
Trial: 32289292
Drug: 3 medications
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 medications
Trial: 33027799
Drug: High tertile
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tertile of net ultrafiltration (NUF) rate (>1.75 mL/kg/h)
Trial: 33027799
Drug: Middle tertile
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle tertile of net ultrafiltration (NUF) rate (1.01-1.75 mL/kg/h)
Trial: 33027799
Drug: Low tertile
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tertile of net ultrafiltration (NUF) rate (<1.01 mL/kg/h)
Trial: 35448970
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based vision therapy